検索結果

ce successful completion of Phase III clinical trials in Japan, which consisted of the comparative (placebo-controlled) trial and the long-term administration trial. During the comparative trial, the ...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

Kong Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, Placebo-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Minoru Kanamoto...

学会发表 | 研究与开发 | 千寿制药株式会社

Kong Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, Placebo-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Minoru Kanamoto...

学会发表 | 研究与开发 | 千寿制药株式会社

Kong Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, Placebo-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Minoru Kanamoto...

学会発表実績 | 研究開発活動 | 千寿製薬株式会社

Kong Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double-Masked, Placebo-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Minoru Kanamoto...